Abnova (Taiwan)TPE:4133 -1.21%75 Gross Margin % is 46.70% as of Dec. 2025, which is 2% above its 10-year median of 45.74. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.30 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, Abnova (Taiwan) ranks worse than 65.58% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Abnova (Taiwan) had a gross margin of 46.70% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Abnova (Taiwan) Gross Margin % Related Terms
Abnova (Taiwan) Gross Margin % Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s Gross Margin % distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Abnova (Taiwan) (TPE:4133) has a Gross Margin % of 46.70% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Abnova (Taiwan) and its competitors. This is near median its historical median of 45.74. Over the past decade, Abnova (Taiwan)'s Gross Margin % has ranged from 43.51 to 48.92. According to the industry distribution chart, Abnova (Taiwan) ranks #482 out of 735 companies in the Biotechnology industry, placing it in the top 65.6%.
Is Abnova (Taiwan)'s Gross Margin % too high?
Abnova (Taiwan)'s current Gross Margin % of 46.70% is near median its 10-year median of 45.74. Over the past 10 years, this metric has ranged from a low of 43.51 to a high of 48.92. The Biotechnology industry median Gross Margin % is 60.90. Abnova (Taiwan)'s value of 46.70% is 23.3% below this industry median. Based on the distribution chart, Abnova (Taiwan) ranks #482 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #482 out of 735 companies for Gross Margin %. This places Abnova (Taiwan) in the lower half of its industry. The industry median Gross Margin % is 60.90. Abnova (Taiwan)'s value of 46.70% is 23.3% below this benchmark. Historically, Abnova (Taiwan)'s own Gross Margin % has ranged from 43.51 to 48.92 over the past decade. While the company's 10-year median is 45.74 vs. the industry median of 60.90, Abnova (Taiwan) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abnova (Taiwan)'s current Gross Margin % of 46.70% is 23.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Abnova (Taiwan) and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abnova (Taiwan)'s current Gross Margin % is 46.70%, which is near median its own 10-year median of 45.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.30, compared to a current price of NT$20.45 — trading 27.7% below its estimated fair value. The current Gross Margin % is 46.70%, which is near median its 10-year median of 45.74 and 23.3% below the Biotechnology industry median of 60.90. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current Gross Margin % is 46.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.45 is trading 27.7% below its estimated GF Value™ of NT$28.30.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
Gross Margin %: 46.70% (near median its 10-year median of 45.74)
GF Value™: NT$28.30 vs. price of NT$20.45 (27.7% below fair value)
Industry Position: 23.3% below the Biotechnology median (#482 of 735)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
